+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antispasmodics Drugs Market by Formulation (Capsule, Injection, Syrup), Route (Oral, Parenteral, Topical), Mechanism, Distribution Channel, Application, End User - Global Forecast 2025-2030- Product Image
Antispasmodics Drugs Market by Formulation (Capsule, Injection, Syrup), Route (Oral, Parenteral, Topical), Mechanism, Distribution Channel, Application, End User - Global Forecast 2025-2030- Product Image
Sale

Antispasmodics Drugs Market by Formulation (Capsule, Injection, Syrup), Route (Oral, Parenteral, Topical), Mechanism, Distribution Channel, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336390
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The antispasmodic drugs market is a dynamic, rapidly evolving sector shaped by diverse therapeutic applications, regulatory influences, and technology-driven advances. Senior decision-makers must stay informed to anticipate changes, optimize portfolios, and navigate rising complexities across the global landscape.

Market Snapshot: Antispasmodics Drugs Market Growth Overview

The Antispasmodics Drugs Market grew from USD 14.70 billion in 2024 to USD 15.95 billion in 2025. It is expected to continue growing at a CAGR of 8.39%, reaching USD 23.85 billion by 2030. Market momentum is driven by expanding chronic disease prevalence, aging demographics, increasing demand for precision therapies, and persistent shifts in reimbursement environments. Innovation in drug formulations, delivery systems, and digital enablement is aligning treatments more closely with individualized patient needs while maintaining robust compliance requirements worldwide.

Scope & Segmentation: Comprehensive Insights Across Key Market Dimensions

  • Formulation Types: Capsules (hard shell and soft gel), Injections (intramuscular, intravenous, subcutaneous), Syrups, and Tablets (coated, uncoated).
  • Administration Routes: Oral, Parenteral (including intramuscular and intravenous), and Topical (cream, gel, patch).
  • Mechanism of Action: Anticholinergics, Calcium Channel Blockers, and GABA Agonists.
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • Therapeutic Applications: Gastrointestinal disorders (irritable bowel syndrome, peptic ulcer, spastic colon), gynecological disorders (dysmenorrhea, endometriosis), urinary disorders (cystitis, overactive bladder).
  • End Users: Clinics, Hospitals.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific. Select key countries include the United States (major states), Canada, Mexico, Brazil, Argentina, the United Kingdom, Germany, France, Russia, China, India, Japan, Australia, and others.
  • Industry Stakeholders: Major pharmaceutical leaders such as Boehringer Ingelheim, Sanofi, Almirall, Teva, Viatris, Sandoz, Pfizer, Dr. Reddy's, Sun Pharma, and Glenmark.
  • Emerging Technologies: Digital health tools for monitoring, nanocarrier-enabled formulations, sustained and extended-release delivery systems, and the rise of pharmacogenomic profiling shaping personalized interventions.

Key Takeaways for Decision-Makers

  • Precision therapies and advanced delivery systems are bringing more patient-tailored antispasmodic treatments to market, fostering improved efficacy and compliance.
  • Expansion into digital health—such as adherence apps and remote monitoring—strengthens patient engagement and enables clinicians to adjust regimens in real time.
  • Strategic collaborations with technology firms, academic partners, and contract manufacturers are shortening development cycles while maintaining quality and cost controls.
  • Segment diversification, including new formulations and targeted mechanisms of action, allows market participants to address a broader mix of clinical scenarios and end-users.
  • Current trends emphasize value demonstration through real-world outcomes, supporting payer negotiations and broadening market access for innovative therapies.
  • Regional differences in regulatory requirements, reimbursement policies, and infrastructure investment call for tailored commercialization strategies for each geography.

Tariff Impact: Navigating 2025 Supply Chain and Manufacturing Challenges

The 2025 tariff adjustments in the United States have prompted significant shifts across the antispasmodic drug supply chain. Manufacturers are reallocating sourcing and synthesis activities to tariff-favorable regions, resulting in optimized margins and minimized operational disruptions. Upgraded inventory and logistics systems now leverage predictive analytics to better manage customs exposure and reduce delays. Partnerships with contract development and manufacturing organizations have been consolidated to achieve economies of scale, ensuring resilience and access in a changing trade environment.

Methodology & Data Sources

This report is built on rigorous multi-layered research methodologies, integrating qualitative and quantitative insights. In-depth interviews with key opinion leaders from various clinical domains, feedback from procurement and regulatory specialists, and input from advisory panels of senior executives provide comprehensive coverage. Peer-reviewed studies, regulatory filings, and proprietary market intelligence further support robust analytical conclusions and reliable trend forecasting.

Why This Report Matters

  • Enables strategic decision-making by distilling actionable intelligence on current and emerging trends within the antispasmodic drugs market.
  • Equips teams to anticipate regional and segment-level opportunities, shaping investment, R&D, and supply chain strategies.
  • Supports operational planning with validated insights on regulatory shifts, supply chain resilience, and stakeholder collaboration models.

Conclusion

The antispasmodic drugs market is advancing through innovation and strategic repositioning. To sustain growth and enhance competitive advantage, leaders must align operational agility with evolving patient and regulatory demands.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising utilization of long acting antispasmodic formulations for improved patient adherence
5.2. Emergence of biosimilar antispasmodic agents driving cost competitive pressure on branded products
5.3. Integration of digital health monitoring tools to track treatment response in spasticity patients
5.4. Growing preference for combination therapies pairing antispasmodics with neuromodulators in clinical practice
5.5. Expansion of antispasmodic drug indications to encompass broader gastrointestinal motility disorders management
5.6. Increased R&D investment in novel selective receptor antagonists targeting smooth muscle hyperactivity control
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Antispasmodics Drugs Market, by Formulation
8.1. Introduction
8.2. Capsule
8.2.1. Hard Shell
8.2.2. Soft Gel
8.3. Injection
8.3.1. Intramuscular
8.3.2. Intravenous
8.3.3. Subcutaneous
8.4. Syrup
8.5. Tablet
8.5.1. Coated
8.5.2. Uncoated
9. Antispasmodics Drugs Market, by Route
9.1. Introduction
9.2. Oral
9.3. Parenteral
9.3.1. Intramuscular
9.3.2. Intravenous
9.4. Topical
9.4.1. Cream
9.4.2. Gel
9.4.3. Patch
10. Antispasmodics Drugs Market, by Mechanism
10.1. Introduction
10.2. Anticholinergics
10.3. Calcium Channel Blockers
10.4. GABA Agonists
11. Antispasmodics Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Antispasmodics Drugs Market, by Application
12.1. Introduction
12.2. Gastrointestinal Disorders
12.2.1. Irritable Bowel Syndrome
12.2.2. Peptic Ulcer
12.2.3. Spastic Colon
12.3. Gynecological Disorders
12.3.1. Dysmenorrhea
12.3.2. Endometriosis
12.4. Urinary Disorders
12.4.1. Cystitis
12.4.2. Overactive Bladder
13. Antispasmodics Drugs Market, by End User
13.1. Introduction
13.2. Clinics
13.3. Hospitals
14. Americas Antispasmodics Drugs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antispasmodics Drugs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antispasmodics Drugs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Boehringer Ingelheim International GmbH
17.3.2. Sanofi S.A.
17.3.3. Almirall, S.A.
17.3.4. Teva Pharmaceutical Industries Ltd.
17.3.5. Viatris Inc.
17.3.6. Sandoz International GmbH
17.3.7. Pfizer Inc.
17.3.8. Dr. Reddy's Laboratories Limited
17.3.9. Sun Pharmaceutical Industries Ltd.
17.3.10. Glenmark Pharmaceuticals Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTISPASMODICS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTISPASMODICS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTISPASMODICS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. ANTISPASMODICS DRUGS MARKET: RESEARCHAI
FIGURE 28. ANTISPASMODICS DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 29. ANTISPASMODICS DRUGS MARKET: RESEARCHCONTACTS
FIGURE 30. ANTISPASMODICS DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTISPASMODICS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HARD SHELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HARD SHELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SOFT GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SOFT GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY COATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY UNCOATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY UNCOATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GEL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GABA AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PEPTIC ULCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY PEPTIC ULCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPASTIC COLON, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY SPASTIC COLON, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY DYSMENORRHEA, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY ENDOMETRIOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CYSTITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CYSTITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ANTISPASMODICS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES ANTISPASMODICS DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 171. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 172. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 173. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 174. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 175. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 176. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 177. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 178. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 179. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 180. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 181. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 182. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 183. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 184. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 185. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 186. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 187. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 190. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 191. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 192. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 193. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 194. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 195. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 196. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 197. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. CANADA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 200. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 201. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 202. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 203. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 204. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 205. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 206. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 207. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 208. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 209. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 210. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 211. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 212. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 213. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 214. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 215. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 220. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 221. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 224. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 225. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. MEXICO ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 235. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 236. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 237. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 238. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 239. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 240. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 241. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 242. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 243. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 261. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 262. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 263. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 264. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 265. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 266. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 267. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 268. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 269. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 270. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 271. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 275. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 276. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 302. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 303. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 304. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 305. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 306. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY GYNECOLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 307. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2018-2024 (USD MILLION)
TABLE 308. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY URINARY DISORDERS, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA ANTISPASMODICS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 315. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
TABLE 316. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY CAPSULE, 2025-2030 (USD MILLION)
TABLE 317. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 318. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 319. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
TABLE 320. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY TABLET, 2025-2030 (USD MILLION)
TABLE 321. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 322. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 324. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 326. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 328. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 329. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 332. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 333. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 334. UNITED KINGDOM ANTISPASMODICS DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, 2025-2030 (

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Antispasmodics Drugs market report include:
  • Boehringer Ingelheim International GmbH
  • Sanofi S.A.
  • Almirall, S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Limited
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 15.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 23.85 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antispasmodics Drugs Market Report 2025 - Product Image

Antispasmodics Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Quadriplegia Treatment Market Report 2025 - Product Image

Quadriplegia Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cerebral Palsy Treatment Market by Treatment Type (Assistive Devices, Pharmacologic Therapies, Rehabilitation Therapies), End User (Home Care Settings, Hospitals, Specialty Clinics), Distribution Channel, Patient Age Group - Global Forecast 2025-2030 - Product Image

Cerebral Palsy Treatment Market by Treatment Type (Assistive Devices, Pharmacologic Therapies, Rehabilitation Therapies), End User (Home Care Settings, Hospitals, Specialty Clinics), Distribution Channel, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Hyoscine - Global Strategic Business Report - Product Image

Hyoscine - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Cerebral Palsy Epidemiology Forecast 2025-2034 - Product Image

Cerebral Palsy Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Muscle Spasm Drug Market

The Muscle Spasm Drug market is a subset of the Central Nervous System Drugs market. It includes drugs used to treat muscle spasms, which are involuntary contractions of the muscles. These drugs are used to reduce pain and discomfort associated with muscle spasms, as well as to improve mobility. Commonly used muscle spasm drugs include muscle relaxants, antispasmodics, and anticonvulsants. These drugs are typically prescribed by a physician and are available in both oral and injectable forms. The Muscle Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, GlaxoSmithKline, Merck, and Sanofi. Other companies in the market include AbbVie, AstraZeneca, Teva Pharmaceuticals, and Mylan. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.